Daiichi-Sankyo Improves Focus

Fresh from offloading interests in active pharmaceutical ingredients (APIs) and diagnostics, Japan's Daiichi-Sankyo has divested its animal health business to Novartis for an undisclosed fee. The development not only reflects Daiichi-Sankyo's focus on medicines for human use, but also heralds the Swiss firm's arrival as a global full-spectrum pharmaceuticals player, present in all product niches ranging from vaccines to

To read the full article, please choose one of the following options: